| HOXB13:IL17BR | MGI | MGI+HOXB13:IL17BR | BCI |  | ||||||
---|---|---|---|---|---|---|---|---|---|---|---|
 | Low (n = 293) | High (n = 315) | Low (n = 248) | High (n = 360) | Low (n = 248) | Intermediate (n = 158) | High (n = 202) | Low (n = 277) | Intermediate (n = 139) | High (n = 192) | Total (n = 608) |
Tumor size (cm) | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | |
   ≤ 1.0 | 97 (58%) | 71 (42%) | 91 (54%) | 77 (46%) | 91 (54%) | 39 (23%) | 38 (23%) | 96 (57%) | 37 (22%) | 35 (21%) | 168 |
   1.1 - 2.0 | 130 (48%) | 141 (52%) | 105 (39%) | 166 (61%) | 105 (39%) | 77 (28%) | 89 (33%) | 119 (44%) | 62 (23%) | 90 (33%) | 271 |
   >2.0 | 66 (39%) | 103 (61%) | 52 (31%) | 117 (69%) | 52 (31%) | 42 (25%) | 75 (44%) | 62 (37%) | 40 (24%) | 67 (40%) | 169 |
Tumor grade1 | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â |
   Well | 95 (66%) | 49 (34%) | 103 (72%) | 41 (28%) | 103 (72%) | 24 (17%) | 17 (12%) | 106 (74%) | 29 (20%) | 9 (6%) | 144 |
   Moderate | 133 (51%) | 128 (49%) | 134 (51%) | 127 (49%) | 134 (51%) | 73 (28%) | 54 (21%) | 144 (55%) | 68 (26%) | 49 (19%) | 261 |
   Poor | 65 (32%) | 138 (68%) | 11 (5%) | 192 (95%) | 11 (5%) | 61 (30%) | 131 (65%) | 27 (13%) | 42 (21%) | 134 (66%) | 203 |
Tumor size and grade2 | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | |
   Group 1 | 129 (66%) | 66 (34%) | 129 (66%) | 66 (34%) | 129 (66%) | 42 (22%) | 24 (12%) | 134 (69%) | 45 (23%) | 16 (8%) | 195 |
   Group 2 | 106 (40%) | 156 (60%) | 80 (31%) | 182 (69%) | 80 (31%) | 76 (29%) | 106 (40%) | 93 (36%) | 60 (23%) | 109 (42%) | 262 |
   Group 3 | 58 (38%) | 93 (62%) | 39 (26%) | 112 (74%) | 39 (26%) | 40 (26%) | 72 (48%) | 50 (33%) | 34 (23%) | 67 (44%) | 151 |
ER status | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â |
   Positive | 274 (53%) | 241 (47%) | 237 (46%) | 278 (54%) | 237 (46%) | 140 (27%) | 138 (27%) | 259 (50%) | 119 (23%) | 137 (27%) | 515 |
   Negative | 19 (20%) | 74 (80%) | 11 (12%) | 82 (88%) | 11 (12%) | 18 (19%) | 64 (69%) | 18 (19%) | 20 (22%) | 55 (59%) | 93 |
PR status | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â |
   Positive | 257 (58%) | 184 (42%) | 211 (48%) | 230 (52%) | 211 (48%) | 126 (29%) | 104 (24%) | 239 (54%) | 99 (22%) | 103 (23%) | 441 |
   Negative | 36 (22%) | 131 (78%) | 37 (22%) | 130 (78%) | 37 (22%) | 23 (19%) | 98 (59%) | 38 (23%) | 40 (24%) | 89 (53%) | 167 |
HER2 status | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â |
   Positive | 12 (16%) | 62 (84%) | 16 (22%) | 58 (78%) | 16 (22%) | 11 (15%) | 47 (64%) | 23 (31%) | 16 (22%) | 35 (47%) | 74 |
   Negative | 281 (53%) | 253 (47%) | 232 (43%) | 302 (57%) | 232 (43%) | 147 (28%) | 155 (29%) | 254 (48%) | 123 (23%) | 157 (29%) | 534 |